Exact Sciences Corp. (NASDAQ: EXAS), a leader in cancer screening and diagnostics, has announced that it will present modeling data assessing the benefits and burdens of established colorectal cancer (CRC) screening strategies, including the Cologuard Plus™ test, at the American College of Gastroenterology (ACG) Annual Meeting. The event will be held from October 25-30, 2024, in Philadelphia, Pennsylvania. Additionally, Exact Sciences will share new data focused on enhancing adherence to CRC screening to address existing gaps.
Exact Sciences is excited to present new modeling data highlighting the Cologuard Plus test as an effective colorectal cancer (CRC) screening strategy across various age groups and screening intervals, thanks to its high sensitivity and specificity for both cancer and precancer. “This data underscores our commitment to continuous innovation and improvement in providing top-tier, patient-centered cancer screening and diagnostic solutions,” said Paul Limburg, MD, MPH, AGAF, chief medical officer for Screening at Exact Sciences.
Researchers utilized a validated simulation model to evaluate the benefit-to-burden ratio of the Cologuard Plus test alongside other established and emerging CRC screening options. Here, benefit was measured in life-years gained, while burden was assessed by the total number of lifetime colonoscopies.
Efficient Frontier Abstract Summary
Title: Next Generation mt-sDNA Offers Optimal Balance of Benefit and Burden for CRC Screening
Summary: The next-generation mt-sDNA test emerged as the only efficient non-invasive screening method for individuals aged 45-75. Blood-based screening strategies did not show efficiency across any age range or screening interval.
Session: Monday, October 28, 2024, 10:30 AM – 4:00 PM EDT
Increasing Real-World Adherence
The remaining seven abstracts focus on patient-centric strategies to boost CRC screening adherence, particularly in underserved populations. Leveraging industry-leading patient navigation and personalized outreach, these initiatives could potentially reduce the CRC screening gap by up to 10% when implemented across the U.S. general population.
ACG Abstracts Overview:
- Cross-Sectional Adherence with the Multi-Target Stool DNA Test (P0437)
Summary: High adherence rates (71.2%) were observed in a national sample of insured individuals aged 45-85, with an average kit return time of 27.3 days.
Session: Sunday, October 27, 2024, 3:30 PM – 7:00 PM EDT - Longitudinal Adherence in a Spanish-Speaking Population (P3827)
Summary: Adherence reached 76.7%, with a mean kit return time of 20.2 days; personalized outreach resulted in over 70% adherence across all age subgroups.
Session: Monday, October 28, 2024, 10:30 AM – 4:00 PM EDT - Gap Closure Adherence Program (P0436)
Summary: Achieved nearly 50% adherence with an average kit return time of 25.5 days, demonstrating mt-sDNA’s effectiveness in enhancing CRC screening participation.
Session: Sunday, October 27, 2024, 3:30 PM – 7:00 PM EDT - Impact of Personalized Patient Outreach (P2120)
Summary: Personalized outreach improved mt-sDNA adherence to 63% compared to 61.1% with standard outreach.
Session: Tuesday, October 29, 2024, 10:30 AM – 4:00 PM EDT - Spanish Language Outreach Impact (P3825)
Summary: Multichannel navigation significantly increased adherence from 45.1% to 51.6% in Spanish-speaking populations.
Session: Monday, October 28, 2024, 10:30 AM – 4:00 PM EDT - Digital Navigation and Adherence (P2118)
Summary: Overall mt-sDNA adherence was 63.7%; SMS + email communication led to the highest adherence at 66.5%.
Session: Monday, October 28, 2024, 10:30 AM – 4:00 PM EDT - Spanish Language Patient Navigation (P3826)
Summary: Spanish-language outreach improved mt-sDNA adherence rates to 62.0% compared to 57.3% for English outreach.
Session: Tuesday, October 29, 2024, 10:30 AM – 4:00 PM EDT
Meet Exact Sciences at ACG
Exact Sciences will host two information sessions at booth #839, led by Burak Ozbay, PhD, MBA, BPharm, Vice President of Health Economics and Outcomes Research. These sessions will focus on precancer detection and insights from modeling CRC screening tests. They will take place on Sunday, October 27, and Monday, October 28, at 5:30 PM and 10:45 AM EDT.
Estimates based on modeling data against U.S. population cohorts, including Medicare Advantage members, U.S. Hispanics, and unscreened citizens.
About the BLUE-C Study
The BLUE-C study was a large, multi-center trial (NCT04144738) involving over 20,000 adults aged 40 and older, designed to evaluate the performance of next-generation Cologuard (multi-target stool DNA or mt-sDNA) against colonoscopy. It is one of the largest colorectal cancer screening trials ever conducted, reflecting the racial and ethnic diversity of the U.S. population as per the 2020 census.
About the Cologuard Plus™ Test
Developed in collaboration with Mayo Clinic, the Cologuard Plus test incorporates novel biomarkers and improved processes, enhancing sample stability to give patients more time to return their samples. Expected to launch in 2025 with Medicare coverage, it aims to offer an improved screening option.
About the Cologuard® Test
Cologuard is a first-line CRC screening test for adults aged 45 and older at average risk, recommended by both the American Cancer Society and the U.S. Preventive Services Task Force. It revolutionized screening by providing a non-invasive option that can be completed at home, with over 16 million tests used in its first decade.
